Biotechnology The US Food and Drug Administration on Friday issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for bardoxolone methyl for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, said the drug’s developer, Reata Pharmaceuticals, whose shares fell 3.7% to $25.16 in after-hours trading. 26 February 2022